Literature DB >> 21631431

Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.

Que T Lambert1, Anuradha Pradhan, J Devon Roll, Gary W Reuther.   

Abstract

Cytokines and their receptors regulate haemopoiesis by controlling cellular growth, survival and differentiation. Thus it is not surprising that mutations of cytokine receptors contribute to the formation of haemopoietic disorders, including cancer. We recently identified transforming properties of IL27R, the ligand-binding component of the receptor for interleukin-27. Although wild-type IL27R exhibits transforming properties in haemopoietic cells, in the present study we set out to determine if the transforming activity of IL27R could be enhanced by mutation. We identified three mutations of IL27R that enhance its transforming activity. One of these mutations is a phenylalanine to cysteine mutation at residue 523 (F523C) in the transmembrane domain of the receptor. The two other mutations identified involve deletions of amino acids in the cytoplasmic juxtamembrane region of the receptor. Expression of each of these mutant IL27R proteins led to rapid cytokine-independent transformation in haemopoietic cells. Moreover, the rate of transformation induced by these mutants was significantly greater than that induced by wild-type IL27R. Expression of these IL27R mutants also induced enhanced activation of JAK (Janus kinase)/STAT (signal transducer and activator of transcription) signalling compared with wild-type. An activating deletion mutation of IL27R enhanced homodimerization of the receptor by a mechanism that may involve disulfide bonding. These transforming IL27R mutants displayed equal or greater transforming activity than bona fide haemopoietic oncogenes such as BCR-ABL (breakpoint cluster region-Abelson murine leukaemia viral oncogene homologue) and JAK2-V617F. Since IL27R is expressed on haemopoietic stem cells, lymphoid cells and myeloid cells, including acute myeloid leukaemia blast cells, mutation of this receptor has the potential to contribute to a variety of haemopoietic neoplasms. © The Authors Journal compilation
© 2011 Biochemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631431      PMCID: PMC3145822          DOI: 10.1042/BJ20110351

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

2.  WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27.

Authors:  Stefan Pflanz; Linda Hibbert; Jeanine Mattson; Rency Rosales; Elena Vaisberg; J Fernando Bazan; Joseph H Phillips; Terrill K McClanahan; Rene de Waal Malefyt; Robert A Kastelein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

3.  Novel retroviral vectors to facilitate expression screens in mammalian cells.

Authors:  Eugene Y Koh; Tong Chen; George Q Daley
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

4.  An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells.

Authors:  Sadahiro Kamiya; Toshiyuki Owaki; Noriko Morishima; Fumio Fukai; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

5.  Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.

Authors:  M O Arcasoy; B A Degar; K W Harris; B G Forget
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

6.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

7.  A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis.

Authors:  Murat O Arcasoy; Aysen F Karayal; Harvey M Segal; Joseph G Sinning; Bernard G Forget
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

8.  Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.

Authors:  G W Reuther; Q T Lambert; M A Caligiuri; C J Der
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 9.  Understanding the pro- and anti-inflammatory properties of IL-27.

Authors:  Alejandro V Villarino; Elaine Huang; Christopher A Hunter
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms.

Authors:  Sophie Lucas; Nico Ghilardi; Ji Li; Frédéric J de Sauvage
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more
  5 in total

Review 1.  Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature.

Authors:  Caroline Andrews; Mairi H McLean; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

Review 2.  JAK2 activation by growth hormone and other cytokines.

Authors:  Michael J Waters; Andrew J Brooks
Journal:  Biochem J       Date:  2015-02-15       Impact factor: 3.857

3.  Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.

Authors:  Rimas J Orentas; James J Yang; Xinyu Wen; Jun S Wei; Crystal L Mackall; Javed Khan
Journal:  Front Oncol       Date:  2012-12-17       Impact factor: 6.244

4.  IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs.

Authors:  Haiyan Jia; Paula Dilger; Chris Bird; Meenu Wadhwa
Journal:  J Interferon Cytokine Res       Date:  2016-01-27       Impact factor: 2.607

Review 5.  Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?

Authors:  Liang Han; Zhe Chen; Kun Yu; Jiahui Yan; Tingting Li; Xin Ba; Weiji Lin; Yao Huang; Pan Shen; Ying Huang; Kai Qin; Yinhong Geng; Yafei Liu; Yu Wang; Shenghao Tu
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.